New Challenges in the Management of Heart Failure: Meet the Experts
This online clinical academic event will focus on recent advances in the management of heart failure. The event consists of two online webinars on consecutive days of approximately 2 hours in duration each.
As the focus of the programme is on practical management of heart failure, the webinar sessions will be based on exemplary clinical cases and guideline recommendations to provide the attendees with up to date expert opinion on the different aspects of pharmacological treatment of heart failure.
All Faculty members are experts of international calibre with extensive clinical and research networks worldwide. Most of them have contributed to the development of national and international management guidelines.
Juan Carlos Kaski
Andrew JS Coats
This webinar is supported by:
12:00 - 12:15
Welcome and introduction-Juan Carlos Kaski & Giuseppe Rosano
12:15 - 12:45
HFpEF - Diagnosis, differences, risk stratification and management - An overview. -Alexander Lyon
12:45 - 13:15
Management of HFrEF - Current guidelines and beyond. -Andrew Coats
13:15 - 13:45
Practical issues in the management of heart failure - comorbidities - FAQ -Panel discussion – Andrew Coats, Alexander Lyon, Giuseppe Rosano
- To gain insight into the most recent developments in the pathophysiology of different forms of heart failure, including HFpEF and HFrEF.
- To briefly discuss non-cardiac treatments affecting heart function i.e. oncological treatments.
- To discuss current international management guidelines and their application to specific cases.
- To gain insight into the management of heart failure patients affected by different co-morbidities such as diabetes and chronic kidney disease.
- To present and discuss the management of iron deficiency and frailty in heart failure.
- The webinar is aimed at cardiac consultants, diabetologists, vascular surgeons, renal physicians, general practitioners with an interest in cardiovascular disease, specialist nurses and other health professionals involved in heart failure, cardiovascular
Juan Carlos Kaski
Juan Carlos Kaski is Professor of Cardiovascular Science at St George’s, University of London (SGUL), Honorary Consultant Cardiologist at St George’s Hospital, NHS Trust, London, UK and Director of the Cardiovascular and Cell Sciences Research Institute at SGUL. Prof Kaski is Doctor of Science, University of London, immediate Past-President of ISCP (International Society of Cardiovascular Pharmacotherapy) and editorial board member and associate editor of numerous peer review journals. He is also fellow of the ESC (FESC), the ACC (FACC), the AHA (FAHA), the Royal College of Physicians (FRCP), and over 30 other scientific societies worldwide.
Prof Kaski’s research areas include mechanisms of rapid coronary artery disease progression, inflammatory and immunological mechanisms of atherosclerosis, microvascular angina and biomarkers of cardiovascular risk. Prof Kaski has published over 400 papers in peer-review journals, over 200 invited papers in cardiology journals and more than 130 book chapters. He has also edited six books on cardiovascular topics.
Professor Kaski’s main areas of research include:
- Microvascular angina and coronary vasospasm
- Inflammation and immunity in cardiovascular disease and acute coronary syndrome
- Biomarkers of cardiovascular risk and rapid coronary artery disease progression
- Pharmacotherapy in stable angina pectoris
Prof Rosano is a consultant cardiologist and honorary professor of cardiology at St George’s University Medical School in London, and scientific director of the Nutramed program at the IRCCS San Raffaele, in Rome, and professor of pharmacology at the University of Catanzaro.
He currently serves as an expert in cardiovascular medicine for the European Assessment Office of the Italian Drug Agency and is a core member of the Cardiovascular Working Party of the European Medicines Agency.
Prof Rosano is a board member of the Heart Failure Association (HFA), and is chairman of the HFA's education committee and the HFA Study Group on Diabetes and Hypertension. He serves as deputy editor-in-chief of Cardiac Failure Review.
Dr Alexander Lyon is a leading London-based consultant cardiologist, specialising in the field of heart failure, cardiomyopathy, cardio-oncology and Takotsubo syndrome. He is highly experienced, and is well-versed in all aspects of cardiology. Along with his private clinics at Royal Brompton Hospital and in central London, he is also senior lecturer for the National Heart and Lung Institute at Imperial College London.
Dr Lyon graduated with a first class degree from Oxford University, and gained experience doing post-graduate training in London and Sydney, Australia before setting up private practice in London. He also holds a PhD. He is renowned for his research into heart failure and Takotsubo syndrome, and is lead for the heart failure research theme of the Biomedical Research Unit at the Royal Brompton Hospital, funded by the National Institute of Health Research (NIHR).
Andrew JS Coats
Prof Coats is Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK. His research greatly influenced the treatment for chronic heart failure, promoting exercise training instead of bed rest. He has a vast experience in education and publishing.
Prof Coats attended Melbourne Grammar School and studied at Oxford and Cambridge. He has a higher doctorates from Oxford (DM) and Imperial (DSc.).
Prof Coats was appointed Viscount Royston Professor of Cardiology at Imperial College in 1996 and Director of Cardiology and Associate Medical Director of the Royal Brompton and Harefield NHS trust. Professor Coats was appointed Dean of Medicine at the University of Sydney in 2002, and subsequently Deputy Vice-Chancellor. Professor Coats was most recently CEO of the Norwich Research Park, the UK's oldest and largest research and innovation park.
Prof Coats research interests are chronic heart failure, hypertension, and organizational behaviour. Professor Coats has a MBA from London Business School, is a Diplomate and Fellow of the Australian Institute of Company Directors and member of the UK Institute of Directors.
1. Vitale C, Jankowska E, Hill L, et al. Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure. Eur J Heart Fail. 2019;21(11):1299-1305
2. Coats AJS. Heart failure management of the elderly patient: focus on frailty, sarcopaenia, cachexia, and dementia: conclusions. Eur Heart J Suppl. 2019;21(Suppl L):L36-L38.
3. Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society [published online ahead of print, 2020 May 28]. Eur J Heart Fail. 2020;10.1002
4. Habibian M, Lyon AR. Monitoring the heart during cancer therapy. Eur Heart J Suppl. 2019;21(Suppl M):M44-M49.
5. Anker MS, Hadzibegovic S, Lena A, et al. Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. ESC Heart Fail. 2019;6(6):1140-1148.
6. Filippo Crea, C. Noel Bairey Merz, John F. Beltrame, Juan Carlos Kaski, et. al. on behalf of the Coronary Vasomotion Disorders International Study Group (COVADIS), The parallel tales of microvascular angina and heart failure with preserved ejection fraction: a paradigm shift, European Heart Journal, Volume 38, Issue 7, 14 February 2017, Pages 473–477